Skip to main content

Cassava Sciences, Inc. (SAVA)

NASDAQ: SAVA · IEX Real-Time Price · USD
45.85
-2.50 (-5.17%)
At close: Dec 3, 2021 4:00 PM
46.21
0.36 (0.79%)
After-hours:Dec 3, 2021 7:59 PM EST
Market Cap1.85B
Revenue (ttm)n/a
Net Income (ttm)-20.83M
Shares Out40.38M
EPS (ttm)-0.56
PE Ration/a
Forward PE101.01
Dividendn/a
Ex-Dividend Daten/a
Volume2,964,340
Open49.13
Previous Close48.35
Day's Range43.49 - 49.90
52-Week Range6.70 - 146.16
Beta0.51
AnalystsBuy
Price Target159.25 (+247.3%)
Earnings DateNov 8, 2021

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, T...

IndustryPharmaceuticals
Founded1998
CEORemi Barbier
Employees11
Stock ExchangeNASDAQ
Ticker SymbolSAVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 159.25, which is an increase of 247.33% from the latest price.

Price Target
$159.25
(247.33% upside)
Analyst Consensus: Buy

News

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term St...

NEW YORK--(BUSINESS WIRE)-- #Cassava--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA) on...

14 hours ago - Business Wire

While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential

If you can stomach the volatility, you may want to enter an appropriately-sized position in SAVA stock. The post While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential appeared firs...

22 hours ago - InvestorPlace

Should Investors Worry About the Federal Investigation of Cassava?

The investigation really isn't the underlying concern.

2 days ago - The Motley Fool

Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Cassava Sciences Just Returned to the Buy Zone

There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeared ...

1 week ago - InvestorPlace

Will Cassava Sciences Stock Continue To See Lower Levels?

The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment -...

2 weeks ago - Forbes

Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam

Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease.  The second Phase 3 study is designed to evaluate the safety and efficacy of o...

2 weeks ago - Benzinga

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program

Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.

2 weeks ago - Zacks Investment Research

Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer's Disease

Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer's Disease Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of...

2 weeks ago - GlobeNewsWire

3 Biotech Stocks That Have More Than Tripled so far This Year

But can they keep up the momentum?

Other symbols:BNTXOCGN
2 weeks ago - The Motley Fool

See Why Cassava Sciences Shares Are Falling On Wednesday?

The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simufilam. ...

2 weeks ago - Benzinga

Why Cassava Sciences Is Sliding Lower Today

Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.

2 weeks ago - The Motley Fool

SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today

Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation. The post SAVA Stock Alert: The SEC Investigation That Has Ca...

2 weeks ago - InvestorPlace

7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside

Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, High...

3 weeks ago - InvestorPlace

Cassava Sciences Reports Third Quarter 2021 Financial Results

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the t...

3 weeks ago - GlobeNewsWire

Cassava Sciences Needs Time and Data to Prove Itself Before You Buy

Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself Bef...

3 weeks ago - InvestorPlace

Cassava Is a Sell After Accusations of Data Manipulation

After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manipul...

3 weeks ago - InvestorPlace

4 Top Biotech Stocks To Watch This Week

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

Other symbols:CORTNVOREGN
3 weeks ago - Stockmarketcom

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop

Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.

Other symbols:ASLEBCTXBGFVPROG
3 weeks ago - InvestorPlace

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when...

Other symbols:ASLEBCTXBGFVPROG
3 weeks ago - Benzinga

Why Did Cassava Sciences Stock Jump 49% Today?

Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheim...

4 weeks ago - Benzinga

Why Cassava Sciences Shares Are Rising

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've ne...

4 weeks ago - Benzinga

SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today

Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.

4 weeks ago - InvestorPlace

Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava S...

It states, “No evidence of data manipulation was found for Western blot data.” It states, “No evidence of data manipulation was found for Western blot data.”

1 month ago - GlobeNewsWire

Is it too risky to buy Cassava Sciences as Quintessential says the stock is worthless?

On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares plunged more than 7% after Quintessential Capital management released a report saying the stock is worthless. The firm called for shorts to swoop...

1 month ago - Invezz